MétaCan
Menu
Retour à la cohorte
Enregistrement W4308378248 · doi:10.1136/jitc-2022-sitc2022.0234

234 Bead-bound antibody-activation of T cells provides sub-optimal metabolic programming and tumour control compared to dendritic cell-activated T cells

2022· article· en· W4308378248 sur OpenAlexaff
Meghan Kates, Gavin Yuen, Michael St. Paul, Alisha R. Elford, Pamela S. Ohashi, Sam Saibil

Notice bibliographique

RevueRegular and Young Investigator Award Abstracts · 2022
Typearticle
Langueen
DomaineMedicine
ThématiqueCAR-T cell therapy research
Établissements canadiensUniversity Health Network
Organismes subventionnairesnon disponible
Mots-clésCD28T cellBiologyCell biologyCytotoxic T cellAntigenDendritic cellCancer researchCD8Molecular biologyImmunologyBiochemistryImmune systemIn vitro

Résumé

récupéré en direct d'OpenAlex

<h3>Background</h3> Adoptive cell therapies (ACT), including chimeric antigen receptor (CAR) or T cell receptor (TCR) transgenic T cells, have demonstrated impressive efficacy for the treatment of cancer. Unfortunately, ACT still does not result in durable responses for many patients.<sup>1</sup> Much investigation has centered around defining the characteristics of T cells that drive the clinical efficacy of ACT. Metabolic programming, and particularly oxidative metabolism, has emerged as a hallmark of T cells associated with superior performance in ACT due to important associations with <i>in vivo</i> persistence and metabolic resiliency in nutrient limiting environments.<sup>2–7</sup> However, further investigation is required to define the optimal <i>ex vivo</i> activation conditions to impart optimal metabolic programming on the T cells used for ACT. We therefore interrogated the difference in metabolic programming resulting from activation with antibody-coated beads versus peptide-pulsed dendritic cells (DCs). <h3>Methods</h3> CD8+ T cells were isolated from P14 TCR transgenic mice (recognizing H2-D<sup>b</sup> gp33 peptide from lymphocytic choriomeningitis virus). T cells were activated with either bone-marrow derived DCs pulsed with gp33 peptide (1:10 DC:T cells) or with bead-bound anti-CD3/anti-CD28 antibodies (1:1 beads:T cells). Oxidative and glycolytic metabolism were measured by Seahorse Extracellular Flux analyzer. These data were used to calculate ATP production rate. <i>In vivo</i>, we examined the performance of these differentially activated P14 T cells to control the growth of subcutaneously implanted B16-gp33 melanoma tumours. <h3>Results</h3> DC-activated T cells showed increased oxidative and glycolytic metabolism compared to bead-bound antibody-activated T cells. This resulted in an enhanced rate of ATP production in the DC-activated T cells. These metabolic data were associated with efficacy in the B16-gp33 model of ACT. Mice treated with DC-activated T cells had significantly diminished tumour growth and improved survival when compared to the bead-bound antibody-activation treatment condition. The latter treatment provided little advantage over the control (no treatment) group. <h3>Conclusions</h3> Bead-bound antibody activation of T cells at a ratio of 1:1 (beads:T cells) provides sub-optimal metabolic priming which is associated with decreased performance in ACT, particularly when compared to DC-activated T cells. Further investigation into the metabolic programming of T cells by different activation conditions may reveal metabolic or signaling modules that can be modified in these conditions to improve therapy. This is relevant to the efficacy of CAR T cell therapy which often uses bead-activation of T cells for clinical protocols. <h3>References</h3> C. H. June, R. S. O’Connor, O. U. Kawalekar, S. Ghassemi, and M. C. Milone, “CAR T cell immunotherapy for human cancer,” <i>Science</i>, vol. <b>359</b>, no. 6382, pp. 1361–1365, Mar. 2018; doi: 10.1126/science.aar6711. S. D. Saibil <i>et al</i>., “Activation of Peroxisome Proliferator-Activated Receptors a and d Synergizes with Inflammatory Signals to Enhance Adoptive Cell Therapy,” <i>Cancer Res</i>, vol. <b>79</b>, no. 3, pp. 445–451, Feb. 2019; doi: 10.1158/0008-5472.CAN-17-3053. M. St Paul <i>et al</i>., “Coenzyme A fuels T cell anti-tumor immunity,” <i>Cell Metab</i>, vol. <b>33</b>, no. 12, pp. 2415-2427.e6, Dec. 2021; doi: 10.1016/j.cmet.2021.11.010. G. J. W. van der Windt <i>et al</i>., “Mitochondrial Respiratory Capacity Is a Critical Regulator of CD8+ T Cell Memory Development,” <i>Immunity</i>, vol. <b>36</b>, no. 1, pp. 68–78, Jan. 2012; doi: 10.1016/j.immuni.2011.12.007. Y. Zhang <i>et al</i>., “Enhancing CD8+ T Cell Fatty Acid Catabolism within a Metabolically Challenging Tumor Microenvironment Increases the Efficacy of Melanoma Immunotherapy,” <i>Cancer Cell</i>, vol. <b>32</b>, no. 3, pp. 377-391.e9, Sep. 2017; doi: 10.1016/j.ccell.2017.08.004. Y. Sun <i>et al</i>., “Zbtb20 Restrains CD8 T Cell Immunometabolism and Restricts Memory Differentiation and Antitumor Immunity,” <i>The Journal of Immunology</i>, vol. <b>205</b>, no. 10, pp. 2649–2666, Nov. 2020; doi: 10.4049/jimmunol.2000459. M. D. Buck <i>et al</i>., “Mitochondrial Dynamics Controls T Cell Fate through Metabolic Programming,” <i>Cell</i>, vol. <b>166</b>, no. 1, pp. 63–76, Jun. 2016; doi: 10.1016/j.cell.2016.05.035. <h3>Ethics Approval</h3> This study was approved by The University Health Network Animal Care Committee; approval number 929.

Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.

Comment cette classification a été obtenuedéplier

Prédiction distillée sur la base complète

Imitation des enseignants

Ni prévalence calibrée, ni vérité terrain. Validation humaine à venir. Apprise à partir de 10 348 étiquettes directes de Codex et de 10 348 étiquettes directes de Gemma. Le mode candidate est l'union des têtes enseignantes seuillées; le consensus est leur intersection. Ces sorties portent le statut machine_predicted_unvalidated et ne sont ni des étiquettes humaines ni des étiquettes directes de modèles de pointe.

score de la tête « metaresearch » (Codex)0,001
score de la tête « metaresearch » (Gemma)0,000
Version: codex-gemma-dda1882f352aStatut de validation: machine_predicted_unvalidated
Catégories candidatesMéta-épidémiologie (sens strict)
Catégories consensuellesaucune
DomaineSignal candidat: aucune · Signal consensuel: aucune
Devis d'étudeSignal candidat: Expérimental (laboratoire) · Signal consensuel: Expérimental (laboratoire)
GenreSignal candidat: Empirique · Signal consensuel: Empirique
Score de désaccord entre enseignants0,026
Score d'incertitude au seuil1,000

Scores Codex et Gemma par catégorie

CatégorieCodexGemma
Métarecherche0,0010,000
Méta-épidémiologie (sens strict)0,0000,000
Méta-épidémiologie (sens large)0,0010,000
Bibliométrie0,0000,000
Études des sciences et des technologies0,0000,000
Communication savante0,0000,000
Science ouverte0,0000,000
Intégrité de la recherche0,0000,001
Charge utile insuffisante (le modèle a refusé de juger)0,0000,000

Scores machine (provisoires)

Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.

Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.

Tête enseignante Opus0,018
Tête enseignante GPT0,273
Écart entre enseignants0,255 · la distance entre les deux têtes enseignantes sur ce seul travail
Statut de validationscore_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découle

Classification

machine, non validée

Prédiction automatique; un appel candidat d’une seule tête enseignante, pas un consensus.

Devis d'étudeExpérimental (laboratoire)
Domainenon disponible
GenreEmpirique

Le détail, modèle par modèle et score par score, se trouve en fin de page sous « Comment cette classification a été obtenue ».

En bref

Citations0
Publié2022
Routes d'admission1
Résumé présentoui

Explorer davantage

Même revueRegular and Young Investigator Award AbstractsMême sujetCAR-T cell therapy researchTravaux en français237 207